WO1993025709A1 - Preparation of nucleic acids - Google Patents
Preparation of nucleic acids Download PDFInfo
- Publication number
- WO1993025709A1 WO1993025709A1 PCT/GB1993/001223 GB9301223W WO9325709A1 WO 1993025709 A1 WO1993025709 A1 WO 1993025709A1 GB 9301223 W GB9301223 W GB 9301223W WO 9325709 A1 WO9325709 A1 WO 9325709A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- sequence
- complementary
- probe
- nucleic acid
- oligonucleotides
- Prior art date
Links
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N35/00—Automatic analysis not limited to methods or materials provided for in any single one of groups G01N1/00 - G01N33/00; Handling materials therefor
- G01N35/0099—Automatic analysis not limited to methods or materials provided for in any single one of groups G01N1/00 - G01N33/00; Handling materials therefor comprising robots or similar manipulators
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01L—CHEMICAL OR PHYSICAL LABORATORY APPARATUS FOR GENERAL USE
- B01L7/00—Heating or cooling apparatus; Heat insulating devices
- B01L7/52—Heating or cooling apparatus; Heat insulating devices with provision for submitting samples to a predetermined sequence of different temperatures, e.g. for treating nucleic acid samples
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6806—Preparing nucleic acids for analysis, e.g. for polymerase chain reaction [PCR] assay
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N35/00—Automatic analysis not limited to methods or materials provided for in any single one of groups G01N1/00 - G01N33/00; Handling materials therefor
- G01N35/0098—Automatic analysis not limited to methods or materials provided for in any single one of groups G01N1/00 - G01N33/00; Handling materials therefor involving analyte bound to insoluble magnetic carrier, e.g. using magnetic separation
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
- B01J2219/00—Chemical, physical or physico-chemical processes in general; Their relevant apparatus
- B01J2219/00274—Sequential or parallel reactions; Apparatus and devices for combinatorial chemistry or for making arrays; Chemical library technology
- B01J2219/00277—Apparatus
- B01J2219/00497—Features relating to the solid phase supports
- B01J2219/005—Beads
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
- B01J2219/00—Chemical, physical or physico-chemical processes in general; Their relevant apparatus
- B01J2219/00274—Sequential or parallel reactions; Apparatus and devices for combinatorial chemistry or for making arrays; Chemical library technology
- B01J2219/00718—Type of compounds synthesised
- B01J2219/0072—Organic compounds
- B01J2219/00722—Nucleotides
-
- C—CHEMISTRY; METALLURGY
- C40—COMBINATORIAL TECHNOLOGY
- C40B—COMBINATORIAL CHEMISTRY; LIBRARIES, e.g. CHEMICAL LIBRARIES
- C40B40/00—Libraries per se, e.g. arrays, mixtures
- C40B40/04—Libraries containing only organic compounds
- C40B40/06—Libraries containing nucleotides or polynucleotides, or derivatives thereof
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N35/00—Automatic analysis not limited to methods or materials provided for in any single one of groups G01N1/00 - G01N33/00; Handling materials therefor
- G01N35/10—Devices for transferring samples or any liquids to, in, or from, the analysis apparatus, e.g. suction devices, injection devices
- G01N35/1081—Devices for transferring samples or any liquids to, in, or from, the analysis apparatus, e.g. suction devices, injection devices characterised by the means for relatively moving the transfer device and the containers in an horizontal plane
- G01N35/109—Devices for transferring samples or any liquids to, in, or from, the analysis apparatus, e.g. suction devices, injection devices characterised by the means for relatively moving the transfer device and the containers in an horizontal plane with two horizontal degrees of freedom
Definitions
- This invention relates to the preparation of nucleic acids and concerns magnetic particles and their use in the preparation of nucleic acids.
- M13 phage is used to obtain single stranded DNA for sequencing templates.
- the traditional methods for M13 DNA purification such as polyethylene glycol (PEG)/phenol procedures (Bankier et al . , [1988], in Wu, R. [ed.] , Methods Enz. 155, 52-93) allow microgram quantities of template to be produced from illilitre volumes.
- thermally cycled sequencing procedures utilising Taq polymerase (Craxton, [1991], Methods: A Companion to Methods in Enzymology 3_, 20-26) only require 200-500ng of - template DNA per reaction. Therefore traditional methods produce an excess of template for most purposes, which wastes both time and money.
- the invention provides a composition comprising magnetic particles, each bearing a plurality of oligonucleotides, each oligonucleotide comprising a sequence, acting as a probe, which is complementary to a sequence under investigation, and further comprising a sequence which is non-complementary to the sequence under investigation.
- the invention provides a method of producing the composition defined above, comprising attaching magnetic particles to an oligonucleotide comprising a complementary probe sequence and further comprising a non-complementary sequence.
- the magnetic particles take the form of beads. Typically these are about 1-5um in diameter. Suitable magnetic beads are commercially available. For instance, they may be obtained from Dynal or, more preferably, from Promega. Those from Promega are found particularly suitable because they have a pitted surface and therefore a higher surface area, which allows greater ' amounts of oligonucleotides to be carried by the bead.
- 'Oligonucleotides' as used herein includes both synthetic and native DNA and RNA sequences of any length.
- the oligonucleotide is preferably single stranded DNA and, conveniently, the complementary probe sequence is substantially 25-45 bases long.
- the non-complementary sequence is generally 5-15 bases in length, typically about 9 bases long.
- the non-complementary sequence of the oligonucleotide acts as a 'linker' joining the complementary probe sequence to the magnetic bead.
- the probe sequence may be attached by either end to the linker oligonucleotide.
- the oligonucleotide may be attached to the magnetic bead by conventional techniques.
- the linker oligonucleotide may conveniently be biotinylated at the end region distal to the end joined to the complementary probe sequence, allowing for ready attachment to streptavidin-coated magnetic beads.
- Other attachment techniques are known to those skilled in the art.
- the probe sequence can, of course, be selected so as to be complementary to any nucleic acid sequence of interest such that, for example, the sequence of interest may be separated from a complex sample by being bound by the magnetic bead/probe and then separated from the rest of the sample by magnetic attraction.
- the invention provides a method of separating a nucleic acid sequence from a sample comprising: contacting a complex sample possibly including the sequence of interest with the composition of the present invention; allowing the sequence of interest, if present, to associate with the composition by means of hybridisation with the complementary probe sequence; and separating the composition and any bound nucleic acid sequences from the rest of the sample by magnetic attraction.
- the complementary probe sequence comprises an oligonucleotide complementary to the sequence of M13.
- the invention therefore provides a method of preparing template DNA for sequencing.
- the probe sequence is complementary to a region upstream from the M13 -21 universal primer site.
- the arrangement described above can confer a number of advantages over prior art methods of purifying nucleic acids.
- the use of a non-complementary linker sequence reduces the likelihood of steric hindrance between the comparatively bulky magnetic bead and the "target" DNA hybridised to the probe. This allows beads prepared in accordance with the invention to bind far more 'target' DNA than possible hitherto.
- probe sequences may become separated from magnetic beads of the prior art by shearing and may act as unwanted "false" primers in subsequent sequencing reactions.
- the non-complementary linker oligonucleotide of the invention ensures that, should the oligonucleotides become separated from the beads, they are far less likely to be able to prime chain-extension reactions. It is a preferred feature therefore that the linker sequence should be at the 3' end of the complementary probe sequence, as this further reduces the risk of non-specific priming.
- the invention provides a method of preparing a DNA sequence of interest from a complex sample comprising: causing lysis of DNA-containing entities by the action of heat in the presence of a suitable detergent; adding magnetic particles attached to a probe complementary to at least part of the sequence of interest together with hybridisation buffer containing a polymer to cause an increase in the effective nucleic acid concentration; allowing the sequence of interest to hybridise to the complementary probe and then separating the particle/probe complex and any sequences hybridised thereto from the rest of the sample by magnetic attraction.
- any magnetic particles to which are attached an appropriate probe are suitable for performing the method defined above, including those already known in the art. However, it is preferred that the particles used are those according to the present invention.
- a suitable detergent is SDS.
- the DNA-containing entities are typically phages.
- a suitable polymer is PEG.
- the use of a polymer to increase the effective concentration of nucleic acid allows smaller volumes of reagents to be used than previously, which in turn enables the method to be performed in a microtitre plate or tray. Similarly, the method is particularly simple and efficient as it employs a target sequence-specific purification step.
- the invention provides a method of preparing DNA by means of a sequence-specific purification step, capable of being performed in a microtitre plate.
- the ability to perform the method in a microtitre plate makes the method of the invention particularly amenable to automation.
- Suitable automated apparatus for performing the method of the invention is described in GB9212164.9 (co-pending Application No PCT/GB93/ ).
- Figure 1 shows the base sequence of a suitable probe/linker oligonucleotide
- Figure 2 shows a photograph of gel electrophoresis performed on DNA prepared by the method of the invention.
- Figure 3 shows a portion of sequencing trace
- the invention involves an oligonucleotide probe which has been synthesised with a biotin group at the 3' end.
- the probe is designed to be complementary to a region upstream from the M13 -21 Universal priming site.
- single plaques may be grown up in culture, the cells harvested and the supernatant collected and lysed to yield free single strands.
- the bead/probe complex is then added, and the probe allowed to anneal to the target DNA. Once bound, the bead/probe/template complex can be separated from the rest of the sample using magnetic attraction and then washed.
- the template may then be freed from the bead/probe complex by heating.
- the procedure is simple and fast. All the post-growth steps can be carried out in microtitre plates with no centrifugation or ethanol precipitations required. In this example, 250 random M13 sub-clones were prepared and se ⁇ uenced using the method outlined below.
- the amount of template recovered depends directly on the design of the probe.
- the probe must be specific to the target but must not act as a secondary sequencing primer if free probe is left in solution. Consequently, the probe is 41bp in length and binds to a region upstream from the M13 -21 Universal primer site.
- the probe has a run of several 'A's at the 3' end together with the biotin group. This acts as a linker arm to prevent steric hindrance between the large streptavidin-coated beads and the binding of the probe to the target. Also the high degree of non-complementarity at the 3 * end would prevent the free probe from acting as a sequencing primer should it shear from the beads.
- the design of the probe is shown in Figure 1, ('B' represents Biotin).
- the probe THM13.3 was synthesised on an ABI 380B DNA synthesiser on a 1uMole scale. Biotin phosphoramidite was obtained frm Amersham U.K. The sequence of the probe was: 5' TAT CGG CCT CAG GAA GAT CGC ACT CCA GCC AGC AAA AAA Biotin A 3' (Seq ID No. 1). Following cleavage from the column, the oligonucleotide was deprotected in ammonia at 55°C overnight. A NAP-10 column was used to purify the crude oligonucleotide. Probe/streptavidin bead linkage
- Promega nucleotide quality beads were used in this example. 1.2ml of Promega beads were used per 12 samples. The beads were washed in 0.1M NaCl three times using a neodymium-iron-boron permanent magnet to separate the beads from the washing solution. 200ul 0.1M NaCl and 1On ol THM13.3 oligonucleotide were then added to 1.2ml( 1.2mg) dry beads and incubated at room temperature for 10 minutes. The beads were then washed 10 times in 0.1M NaCl to remove unbound oligonucleotide. Bead/probe complex was finally taken up in 1.2ml water. Beads may be bound to probe in bulk and stored in storage buffer at 4°C.
- Random M13 sub-clones with 1-2kb inserts were grown up in 2ml 2xTy medium (16g bacto tryptone, 10g yeast extract, 5g NaCl in 11 water) for 5 hours at 37°C. Cells were spun down at 14,000g for 5 minutes and the supernatant transferred to microtitre plates. 400ul supernatant was used from each sample, using two wells, each containing 200ul supernatant (Falcon 3911 MicroTest Flexible Assay Plate. )
- the microtitre plate was removed from the cycler and placed on a Dynal MPC-96 magnetic separator. After 30 seconds the supernatant was aspirated, 100ul wash buffer (0.1X SSC) were added to each well and the beads were moved through the wash buffer by repositioning the plate over the magnetic separator three times at intervals of five seconds. This step was repeated a total of three times. Finally, the beads were eluted in 10ul water; using the magnet, beads may be dispersed into this small volume.
- 100ul wash buffer 0.1X SSC
- the templates were released from the probe by heating the plate to 80 C for 3 minutes. After heating, the beads were concentrated using the magnet and the supernatant was removed to a fresh microtitre plate. Due to evaporation the final total volume was approximately 8ul from each well, or approximately 16ul per DNA template sample.
- FIG. 2 The efficacy of the technique is illustrated by Figure 2.
- Four random M13 subclones were grown as described. The cells were harvested and the supernatant (1200ul) was split three ways to provide three identical samples. A, B and C (400ul each). For each sub clone. Sample A was prepared using the method outlined previously. Sample B was prepared as outlined but leaving out the hybridisation buffer (20% PEG/2.5M NaCl). Sample C was prepared as outlined but using magnetic beads without a probe attached. The samples were then subjected to agarose gel electrophoresis. This showed that when the PEG is removed there is a dramatic reduction in yield, as expected. When beads are used without probe attached the resulting yield is zero. The difference between this control and the method of Alderton et al., (1992), is that in sample C the phage are lysed before addition of PEG.
- beads may be re-used as outlined below.
- Beads were collected and pooled in a 1.5ml eppendorf tube. The supernatant was removed and the beads were resuspended in 1ml reuse buffer (0.15M NaOH, 0.001% Tween 20) for 1 minute. The supernatant was removed and the procedure repeated. Finally the beads were washed once in storage buffer and taken up in half the original volume of storage buffer (PBS pH 7.5, 0.1% BSA). Beads were then stored at 4°C.
- a preferred feature of the method of preparing DNA is to bring about magnetic attraction for the magnetic beads by the use of a "dot magnet".
- a typical microtitre assay plate generally 130 mm by 85 mm
- the dot magnet comprises an array of 96 such rare earth magnets which are positioned in a matrix 8 x 12 and are separated by about 9mm from each nearest neighbour (ie. substantially the same spacing as that between the wells of a microtitre plate) thus when the sides of the dot magnet are aligned with the sides of a typical microtitre plate, each rare earth magnet is positioned beneath a well in the microtitre plate.
- MOLECULE TYPE DNA (genomic)
- HYPOTHETICAL NO
- ANTI-SENSE NO
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Analytical Chemistry (AREA)
- Biochemistry (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Physics & Mathematics (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Physics & Mathematics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Pathology (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Clinical Laboratory Science (AREA)
- Biophysics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Robotics (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Saccharide Compounds (AREA)
Abstract
Disclosed is a composition comprising magnetic particles, each bearing a plurality of oligonucleotides, each oligonucleotide comprising a sequence, acting as a probe, which is complementary to a sequence under investigation, and further comprising a sequence which is non-complementary to the sequence under investigation. Also disclosed is a method of purifying a nucleic acid using the composition of the invention and a method of preparing a nucleic acid.
Description
Title Preparation of Nucleic Acids
Field of the Invention
This invention relates to the preparation of nucleic acids and concerns magnetic particles and their use in the preparation of nucleic acids.
Background of the Invention
Currently, a number of large scale DNA sequencing projects are under way. One of the rate-limiting steps in the generation of sequence data is the preparation of high purity DNA templates.
Typically, M13 phage is used to obtain single stranded DNA for sequencing templates. The traditional methods for M13 DNA purification, such as polyethylene glycol (PEG)/phenol procedures (Bankier et al . , [1988], in Wu, R. [ed.] , Methods Enz. 155, 52-93) allow microgram quantities of template to be produced from illilitre volumes. However, thermally cycled sequencing procedures utilising Taq polymerase (Craxton, [1991], Methods: A Companion to Methods in Enzymology 3_, 20-26) only require 200-500ng of - template DNA per reaction. Therefore traditional methods produce an excess of template for most purposes, which wastes both time and money.
Some alternative methods of preparing template DNA have been described which employ a microtitre-scale format, and
thereby reduce waste. For example, one method uses specialised filtration steps (Kristensen et al., [1987], Nucleic Acids Research 1_5_, 5507-5516), whilst another (Smith et al. , [1990], Journal of DNA Sequencing and Mapping λ_, 73-78) requires the use of PEG/sodium dodecyl sulphate (SDS) with multiple centrifugation steps. Thus these alternative techniques are somewhat cumbersome and impractical.
More recently, a protocol has been described (Alderton et al., [1992], Analytical Biochemistry 152, 304-307) which utilises magnetic particles together with PEG-phage aggregation. A somewhat similar method is disclosed in WO90/06045. This outlines a method of preparing DNA using magnetic beads coated with oligonucleotides, which serve as hybridisation probes, to form a magnetic bead/probe complex. The magnetic beads and any bound nucleic acids can then be magnetically separated from the rest of the sample. However, further improvements in this technology are possible as disclosed below.
Summary of Invention
In one aspect the invention provides a composition comprising magnetic particles, each bearing a plurality of oligonucleotides, each oligonucleotide comprising a sequence, acting as a probe, which is complementary to a sequence under investigation, and further comprising a sequence which is non-complementary to the sequence under investigation.
In another aspect, the invention provides a method of producing the composition defined above, comprising attaching magnetic particles to an oligonucleotide
comprising a complementary probe sequence and further comprising a non-complementary sequence.
Conveniently, the magnetic particles take the form of beads. Typically these are about 1-5um in diameter. Suitable magnetic beads are commercially available. For instance, they may be obtained from Dynal or, more preferably, from Promega. Those from Promega are found particularly suitable because they have a pitted surface and therefore a higher surface area, which allows greater 'amounts of oligonucleotides to be carried by the bead.
'Oligonucleotides' as used herein includes both synthetic and native DNA and RNA sequences of any length. However, the oligonucleotide is preferably single stranded DNA and, conveniently, the complementary probe sequence is substantially 25-45 bases long. The non-complementary sequence is generally 5-15 bases in length, typically about 9 bases long.
Preferably, the non-complementary sequence of the oligonucleotide acts as a 'linker' joining the complementary probe sequence to the magnetic bead. The probe sequence may be attached by either end to the linker oligonucleotide.
The oligonucleotide may be attached to the magnetic bead by conventional techniques. For example, the linker oligonucleotide may conveniently be biotinylated at the end region distal to the end joined to the complementary probe sequence, allowing for ready attachment to streptavidin-coated magnetic beads. Other attachment techniques are known to those skilled in the art.
The probe sequence can, of course, be selected so as to be complementary to any nucleic acid sequence of interest such that, for example, the sequence of interest may be separated from a complex sample by being bound by the magnetic bead/probe and then separated from the rest of the sample by magnetic attraction.
Thus in another aspect the invention provides a method of separating a nucleic acid sequence from a sample comprising: contacting a complex sample possibly including the sequence of interest with the composition of the present invention; allowing the sequence of interest, if present, to associate with the composition by means of hybridisation with the complementary probe sequence; and separating the composition and any bound nucleic acid sequences from the rest of the sample by magnetic attraction.
Typically the complementary probe sequence comprises an oligonucleotide complementary to the sequence of M13. In a preferred arrangement the invention therefore provides a method of preparing template DNA for sequencing.
Generally the probe sequence is complementary to a region upstream from the M13 -21 universal primer site.
The arrangement described above can confer a number of advantages over prior art methods of purifying nucleic acids. The use of a non-complementary linker sequence reduces the likelihood of steric hindrance between the comparatively bulky magnetic bead and the "target" DNA hybridised to the probe. This allows beads prepared in accordance with the invention to bind far more 'target' DNA than possible hitherto.
Furthermore, when preparing DNA for sequencing reactions, probe sequences may become separated from magnetic beads of the prior art by shearing and may act as unwanted "false" primers in subsequent sequencing reactions. However, the non-complementary linker oligonucleotide of the invention ensures that, should the oligonucleotides become separated from the beads, they are far less likely to be able to prime chain-extension reactions. It is a preferred feature therefore that the linker sequence should be at the 3' end of the complementary probe sequence, as this further reduces the risk of non-specific priming.
Conventional methods of preparing template DNA from M13 typically involve aggregation of phage particles at room temperature by the use of PEG/NaCl solutions (typically 20% PEG/2.5M NaCl), followed by lysis with SDS to release DNA, which is then bound to the magnetic bead/probe complex. However, it has now been found that advantages accrue from a novel DNA preparation protocol in which M13 particles are first lysed by the action of heat in the presence of a suitable detergent such as SDS. Subsequently, probe/bead complex is added, together with hybridisation buffer containing a suitable polymer such as PEG. Whereas in conventional methods PEG is used to bring about aggregation of the phage particles, in the novel method of the invention it is added after phage lysis to effectively increase the concentration of the target DNA by excluding nucleic acids from the volume taken up by the polymer (Amasino et al., [1992], Analytical Biochemistry 201, 166-169).
Thus in another aspect the invention provides a method of
preparing a DNA sequence of interest from a complex sample comprising: causing lysis of DNA-containing entities by the action of heat in the presence of a suitable detergent; adding magnetic particles attached to a probe complementary to at least part of the sequence of interest together with hybridisation buffer containing a polymer to cause an increase in the effective nucleic acid concentration; allowing the sequence of interest to hybridise to the complementary probe and then separating the particle/probe complex and any sequences hybridised thereto from the rest of the sample by magnetic attraction.
Any magnetic particles to which are attached an appropriate probe are suitable for performing the method defined above, including those already known in the art. However, it is preferred that the particles used are those according to the present invention.
A suitable detergent is SDS.
The DNA-containing entities are typically phages.
A suitable polymer is PEG. The use of a polymer to increase the effective concentration of nucleic acid allows smaller volumes of reagents to be used than previously, which in turn enables the method to be performed in a microtitre plate or tray. Similarly, the method is particularly simple and efficient as it employs a target sequence-specific purification step.
Thus the invention provides a method of preparing DNA by means of a sequence-specific purification step, capable of being performed in a microtitre plate.
The ability to perform the method in a microtitre plate makes the method of the invention particularly amenable to automation. Suitable automated apparatus for performing the method of the invention is described in GB9212164.9 (co-pending Application No PCT/GB93/ ).
The various aspects of the invention may be better understood by reference to the following illustrative example and drawings in which:
Figure 1 shows the base sequence of a suitable probe/linker oligonucleotide;
Figure 2 shows a photograph of gel electrophoresis performed on DNA prepared by the method of the invention; and
Figure 3 shows a portion of sequencing trace
Example
In this particular example, the invention involves an oligonucleotide probe which has been synthesised with a biotin group at the 3' end. The probe is designed to be complementary to a region upstream from the M13 -21 Universal priming site.
In general, single plaques may be grown up in culture, the cells harvested and the supernatant collected and lysed to yield free single strands. The bead/probe complex is then added, and the probe allowed to anneal to the target DNA. Once bound, the bead/probe/template complex can be separated from the rest of the sample using magnetic
attraction and then washed. The template may then be freed from the bead/probe complex by heating. The procedure is simple and fast. All the post-growth steps can be carried out in microtitre plates with no centrifugation or ethanol precipitations required. In this example, 250 random M13 sub-clones were prepared and seσuenced using the method outlined below.
Probe Design
The amount of template recovered depends directly on the design of the probe. The probe must be specific to the target but must not act as a secondary sequencing primer if free probe is left in solution. Consequently, the probe is 41bp in length and binds to a region upstream from the M13 -21 Universal primer site. The probe has a run of several 'A's at the 3' end together with the biotin group. This acts as a linker arm to prevent steric hindrance between the large streptavidin-coated beads and the binding of the probe to the target. Also the high degree of non-complementarity at the 3 * end would prevent the free probe from acting as a sequencing primer should it shear from the beads. The design of the probe is shown in Figure 1, ('B' represents Biotin).
The probe THM13.3 was synthesised on an ABI 380B DNA synthesiser on a 1uMole scale. Biotin phosphoramidite was obtained frm Amersham U.K. The sequence of the probe was: 5' TAT CGG CCT CAG GAA GAT CGC ACT CCA GCC AGC AAA AAA Biotin A 3' (Seq ID No. 1). Following cleavage from the column, the oligonucleotide was deprotected in ammonia at 55°C overnight. A NAP-10 column was used to purify the crude oligonucleotide.
Probe/streptavidin bead linkage
Promega nucleotide quality beads were used in this example. 1.2ml of Promega beads were used per 12 samples. The beads were washed in 0.1M NaCl three times using a neodymium-iron-boron permanent magnet to separate the beads from the washing solution. 200ul 0.1M NaCl and 1On ol THM13.3 oligonucleotide were then added to 1.2ml( 1.2mg) dry beads and incubated at room temperature for 10 minutes. The beads were then washed 10 times in 0.1M NaCl to remove unbound oligonucleotide. Bead/probe complex was finally taken up in 1.2ml water. Beads may be bound to probe in bulk and stored in storage buffer at 4°C.
M13 Sub-clones
Random M13 sub-clones with 1-2kb inserts were grown up in 2ml 2xTy medium (16g bacto tryptone, 10g yeast extract, 5g NaCl in 11 water) for 5 hours at 37°C. Cells were spun down at 14,000g for 5 minutes and the supernatant transferred to microtitre plates. 400ul supernatant was used from each sample, using two wells, each containing 200ul supernatant (Falcon 3911 MicroTest Flexible Assay Plate. )
Lysis
Prior to addition of supernatant, 10ul of 15% SDS was added to each well using an Eppendorf multidispensing pipette. Phages were lysed by heating the microtitre plate to 70 C for 10 minutes on a Techne PHC-3 cycler
Annealing
20ul of hybridisation buffer (20% PEG 8000/2.5M NaCl) was added to each well with a multidispensing pipette; no mixing is required so the same tip may be used for all wells. Also, 20ul bead/probe complex were added to each well, and the dish was incubated at 45°C for 30 minutes.
Wash Steps
The microtitre plate was removed from the cycler and placed on a Dynal MPC-96 magnetic separator. After 30 seconds the supernatant was aspirated, 100ul wash buffer (0.1X SSC) were added to each well and the beads were moved through the wash buffer by repositioning the plate over the magnetic separator three times at intervals of five seconds. This step was repeated a total of three times. Finally, the beads were eluted in 10ul water; using the magnet, beads may be dispersed into this small volume.
Denaturation
The templates were released from the probe by heating the plate to 80 C for 3 minutes. After heating, the beads were concentrated using the magnet and the supernatant was removed to a fresh microtitre plate. Due to evaporation the final total volume was approximately 8ul from each well, or approximately 16ul per DNA template sample.
The efficacy of the technique is illustrated by Figure 2. Four random M13 subclones were grown as described. The cells were harvested and the supernatant (1200ul) was split three ways to provide three identical samples. A, B and C (400ul each). For each sub clone. Sample A was
prepared using the method outlined previously. Sample B was prepared as outlined but leaving out the hybridisation buffer (20% PEG/2.5M NaCl). Sample C was prepared as outlined but using magnetic beads without a probe attached. The samples were then subjected to agarose gel electrophoresis. This showed that when the PEG is removed there is a dramatic reduction in yield, as expected. When beads are used without probe attached the resulting yield is zero. The difference between this control and the method of Alderton et al., (1992), is that in sample C the phage are lysed before addition of PEG.
Sequencing Results
Once the templates have been purified, as described above, it is possible to immediately perform the sequencing reactions as pre-reaction mixes can be made up and dispensed in advance. The ABI Taq dye primer kit reagents were used. The total volume after recovery of the template from the probe varies from 14-16ul. From this, 2ul has been used in the A/C reactions and 4ul in the G/T reactions. The volume variability does not reduce the quality of the sequence data. All samples were sequenced using the M13 -21 universal primer and Taq polymerase. The reactions were cycled on a Techne PHC-3 dry cycler, each sample being covered with mineral oil. The reaction products were analysed on an ABI 373A DNA sequencer.
In this study, 250 clones taken from the C. elegans cosmids ZK507, ZK512 and K01B6 were prepared using the magnetic probe method and sequenced as described above. The method gave reproducible high quality data which was assembled into current databases. Figure 3 shows a section of a read. The trace shows bases 125-375 from. a
random M13 sub-clone containing a 1-2kb insert. From the sequence data available, it is clear that the procedure is reproducible and not sensitive to fluctuations in template or bead concentrations. Few sub-clones failed to give sequence and overall the results were comparable to the standard PEG/phenol method.
Re-use of Beads
After the preparation of a batch of DNA samples, beads may be re-used as outlined below.
Beads were collected and pooled in a 1.5ml eppendorf tube. The supernatant was removed and the beads were resuspended in 1ml reuse buffer (0.15M NaOH, 0.001% Tween 20) for 1 minute. The supernatant was removed and the procedure repeated. Finally the beads were washed once in storage buffer and taken up in half the original volume of storage buffer (PBS pH 7.5, 0.1% BSA). Beads were then stored at 4°C.
As will be apparent, the preparation steps described above can conveniently be carried out using automated apparatus, for example as described in GB9212164.9 (co-pending international application No PCT/GB93/ ).
In an alternative method, 50 ul of hydridisation buffer is added to each well, instead of 20 ul as described above, and the volume of beads added to the well reduced slightly to compensate. This enables sufficient template DNA to be obtained from just 200 ul of M13 supernatant (instead of 400 ul as described above). Thus 1 microtitre plate well is sufficient for the analysis of 1 clone, whereas previously 2 wells were required to obtain sufficient
template DNA from each clone analysed. As a result, twice as many clones can be studied per microtitre plate than was the case previously.
A preferred feature of the method of preparing DNA is to bring about magnetic attraction for the magnetic beads by the use of a "dot magnet". This is a device with the dimensions of a typical microtitre assay plate (generally 130 mm by 85 mm) which comprises an array of rare earth magnets. Preferably the dot magnet comprises an array of 96 such rare earth magnets which are positioned in a matrix 8 x 12 and are separated by about 9mm from each nearest neighbour (ie. substantially the same spacing as that between the wells of a microtitre plate) thus when the sides of the dot magnet are aligned with the sides of a typical microtitre plate, each rare earth magnet is positioned beneath a well in the microtitre plate.
SEQUENCE LISTING
(1) GENERAL INFORMATION: (i) APPLICANT:
(A NAME: Medical Research Council (B STREET: 20 Park Crescent (C CITY: London (E COUNTRY: United Kingdom (F POSTAL CODE (ZIP): WIN 4AL (G TELEPHONE: (071) 636 5422 (H TELEFAX: (071) 323 1331
(A NAME: Hawkins, Trevor L. , (B STREET: Promega Corp., 2800 Woods Hollow Road (C CITY: Madison (D STATE: Wisconsin (E COUNTRY: U.S.A. (F POSTAL CODE (ZIP): 53711-5399
(ii) TITLE OF INVENTION: Preparation of Nucleic Acids (iii) NUMBER OF SEQUENCES: 1
(iv) COMPUTER READABLE FORM:
(A) MEDIUM TYPE: Floppy disk
(B) COMPUTER: IBM PC compatible
(C) OPERATING SYSTEM: PC-DOS/MS-DOS
(D) SOFTWARE: Patentln Release #1.0, Version #1.25 (EPO)
(2) INFORMATION FOR SEQ ID NO: 1:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 40 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: DNA (genomic) (iii) HYPOTHETICAL: NO (iii) ANTI-SENSE: NO
(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 1: TATCGGCCTC AGGAAGATCG CACTCCAGCC AGCAAAAAAA 40
SUBSTITUTESHEET
Claims
1. A composition comprising magnetic particles, each bearing a plurality of oligonucleotides, each oligonucleotide comprising a sequence, acting as a probe, which is complementary to a sequence under investigation, and further comprising a sequence which is non- complementary to the sequence under investigation.
2. A composition according to claim 1, wherein the magnetic particle comprises a bead of l-5um in diameter.
3. A composition according to claim 1 or 2, wherein the oligonucleotides are single stranded DNA.
4. A composition according to any of claims 1, 2 or 3, wherein the complementrary probe sequence of the oligonucleotides is in the range 25-45 bases long.
5. A composition according to any one of the preceding claims, wherein the complementary probe sequence is complementary to M13.
6. A composition according to any one of the preceding claims, wherein the non-complementary sequence of the oligonucleotides is in the range 5-15 bases long.
7. A composition according to any one of the preceding claims, wherein the non-complementary sequence of the oligonuleotides is biotinylated.
8. A composition according to any one of the preceding claims, wherein the non-complementary sequence of the oligonucleotides acts as a linker between the magnetic particle and the complementary probe sequence of the oligonucleotides.
9. A composition according to any one of the preceding claims, wherein the non-complementary sequence of the oligonucleotides is at the 3' end of the complementary probe sequence.
10. A method of making the composition of any one of claims 1-9, comprising attaching magnetic particles to an oligonucleotide comprising a complementary probe sequence and further comprising a non-complementary sequence.
11. A method of separating a nucleic acid sequence from a sample, comprising: contacting a complex sample possibly including the sequence of interest with the composition according to any one of claims 1-9; allowing the sequence of interest, if present, to associate with the composition by means of hybridisation with the complementary probe sequence; and separating the particles and any bound nucleic acid sequences from the rest of the sample by magnetic attraction.
12. A method according to claim 11, wherein the sequence of interest comprises a DNA sequence to be determined.
13. A method of preparing a nucleic acid sequence of interest from a complex sample, comprising: causing lysis of nucleic acid-containing entities by the action of heat in the presence of a suitable detergent; adding magnetic particles attached to a probe complementary to at least part of the sequence of interest (hereinafter "particle/probe complex"), together with hydridisation buffer containing a polymer to cause an increase in the effective nucleic acid concentration; allowing the sequence of interest to hybridise to the complementary probe; and then separating the particle/probe complex and any sequences hybridised thereto from the rest of the sample by magnetic attraction.
14. A method according to claim 13, wherein the detergent is SDS.
15. A method according to claim 13 or 14, wherein the nucleic acid-containing entity is a bacteriophage.
16. A method according to any one of claims 13-15, wherein the nucleic acid is DNA.
17. A method according to any one of claims 13-16 wherein the particle/probe complex is comprised within a composition in accordance with any one of claims 1-9.
18. A method of preparing a nucleic acid by means of a sequence-specific purification step performed in a microtitre plate.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AU43440/93A AU4344093A (en) | 1992-06-09 | 1993-06-09 | Preparation of nucleic acids |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB929212164A GB9212164D0 (en) | 1992-06-09 | 1992-06-09 | Preparation of nucleic acids |
GB9212164.9 | 1992-06-09 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO1993025709A1 true WO1993025709A1 (en) | 1993-12-23 |
Family
ID=10716759
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/GB1993/001223 WO1993025709A1 (en) | 1992-06-09 | 1993-06-09 | Preparation of nucleic acids |
PCT/GB1993/001222 WO1993025912A2 (en) | 1992-06-09 | 1993-06-09 | Automated preparation of nucleic acids |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/GB1993/001222 WO1993025912A2 (en) | 1992-06-09 | 1993-06-09 | Automated preparation of nucleic acids |
Country Status (3)
Country | Link |
---|---|
AU (2) | AU4343993A (en) |
GB (1) | GB9212164D0 (en) |
WO (2) | WO1993025709A1 (en) |
Cited By (27)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1996009379A1 (en) * | 1994-09-20 | 1996-03-28 | Whitehead Institute For Biomedical Research | Dna purification and isolation using a solid phase |
US5683875A (en) * | 1995-05-04 | 1997-11-04 | Hewlett-Packard Company | Method for detecting a target nucleic acid analyte in a sample |
DE19801730A1 (en) * | 1998-01-19 | 1999-07-22 | Fraunhofer Ges Forschung | Analyzing cell contents, especially nucleic acids, useful for medical diagnostics |
DE19943374A1 (en) * | 1999-09-10 | 2001-03-29 | Max Planck Gesellschaft | Method for binding nucleic acids to a solid phase |
WO2001051665A2 (en) * | 2000-01-13 | 2001-07-19 | Nanosphere Inc. | Nanoparticles having oligonucleotides attached thereto and uses therefor |
WO2001073123A2 (en) * | 2000-03-28 | 2001-10-04 | Nanosphere Inc. | Nanoparticles having oligonucleotides attached thereto and uses therefor |
WO2002018643A2 (en) * | 2000-08-11 | 2002-03-07 | Nanosphere Inc. | Nanoparticles having oligonucleotides attached thereto and uses therefor |
WO2002046472A2 (en) * | 2000-12-08 | 2002-06-13 | Nanosphere, Inc. | Nanoparticles having oligonucleotides attached thereto and uses therefor |
US6582921B2 (en) | 1996-07-29 | 2003-06-24 | Nanosphere, Inc. | Nanoparticles having oligonucleotides attached thereto and uses thereof |
US6602669B2 (en) | 2000-07-11 | 2003-08-05 | Northwestern University | Method of detection by enhancement of silver staining |
US6645721B2 (en) | 1996-07-29 | 2003-11-11 | Nanosphere, Inc. | Nanoparticles having oligonucleotides attached thereto and uses therefor |
US6750016B2 (en) | 1996-07-29 | 2004-06-15 | Nanosphere, Inc. | Nanoparticles having oligonucleotides attached thereto and uses therefor |
US6773884B2 (en) | 1996-07-29 | 2004-08-10 | Nanosphere, Inc. | Nanoparticles having oligonucleotides attached thereto and uses therefor |
US6812334B1 (en) | 1996-07-29 | 2004-11-02 | Nanosphere, Inc. | Nanoparticles having oligonucleotides attached thereto and uses therefor |
US6974669B2 (en) | 2000-03-28 | 2005-12-13 | Nanosphere, Inc. | Bio-barcodes based on oligonucleotide-modified nanoparticles |
US6977178B2 (en) | 2000-09-06 | 2005-12-20 | Transnetyx, Inc. | System and method for transgenic and targeted mutagenesis screening |
US6984491B2 (en) | 1996-07-29 | 2006-01-10 | Nanosphere, Inc. | Nanoparticles having oligonucleotides attached thereto and uses therefor |
WO2006059386A1 (en) * | 2004-12-02 | 2006-06-08 | National Institute Of Agrobiological Sciences | Method of isolating double-stranded dna containing simple sequence repeats |
US7115688B1 (en) | 1998-11-30 | 2006-10-03 | Nanosphere, Inc. | Nanoparticles with polymer shells |
US7135055B2 (en) | 2001-05-25 | 2006-11-14 | Nanosphere, Inc. | Non-alloying core shell nanoparticles |
US7147687B2 (en) | 2001-05-25 | 2006-12-12 | Nanosphere, Inc. | Non-alloying core shell nanoparticles |
US7169556B2 (en) | 1996-07-29 | 2007-01-30 | Nanosphere, Inc. | Nanoparticles having oligonucleotides attached thereto and uses therefor |
US7186814B2 (en) | 2001-11-09 | 2007-03-06 | Nanosphere, Inc. | Bioconjugate-nanoparticle probes |
US7253277B2 (en) | 2002-07-02 | 2007-08-07 | Nanosphere, Inc. | Nanoparticle polyanion conjugates and methods of use thereof in detecting analytes |
US7494817B2 (en) | 2000-09-06 | 2009-02-24 | Transnet Yx, Inc. | Methods for genotype screening using magnetic particles |
US7527929B2 (en) | 2004-07-30 | 2009-05-05 | Agencourt Bioscience Corporation | Methods of isolating nucleic acids using multifunctional group-coated solid phase carriers |
US8691969B2 (en) | 1994-12-12 | 2014-04-08 | Life Technologies As | Isolation of nucleic acid |
Families Citing this family (30)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE4409436A1 (en) * | 1994-03-19 | 1995-09-21 | Boehringer Mannheim Gmbh | Process for processing nucleic acids |
DE4421058A1 (en) | 1994-06-16 | 1995-12-21 | Boehringer Mannheim Gmbh | Process for the magnetic separation of liquid components |
EP0784796A4 (en) * | 1994-10-07 | 1998-11-11 | Flinders Technologies Pty Ltd | Apparatus and method for storage, purification or reaction and processing of a biopolymer |
DE19512368A1 (en) * | 1995-04-01 | 1996-10-02 | Boehringer Mannheim Gmbh | Nucleic acid release and isolation system |
US6919175B1 (en) | 1995-04-01 | 2005-07-19 | Roche Diagnostics Gmbh | System for releasing and isolating nucleic acids |
US6277332B1 (en) | 1995-12-18 | 2001-08-21 | Solid Phase Sciences Corporation | Reaction plenum with magnetic separation and/or ultrasonic agitation |
US5779985A (en) * | 1995-12-18 | 1998-07-14 | Solid Phase Sciences Corporation | Reaction plenum |
GB9525794D0 (en) * | 1995-12-18 | 1996-02-21 | Hale Alan | Biotechnological process |
US6008010A (en) | 1996-11-01 | 1999-12-28 | University Of Pittsburgh | Method and apparatus for holding cells |
FR2760844B1 (en) * | 1997-03-17 | 1999-05-21 | Genethon Ii | DEVICE AND METHOD FOR AUTOMATIC ANALYSIS OF SAMPLES ON GELS |
US5912129A (en) * | 1998-03-05 | 1999-06-15 | Vinayagamoorthy; Thuraiayah | Multi-zone polymerase/ligase chain reaction |
AU2006230730B2 (en) * | 1998-05-01 | 2009-03-05 | Gen-Probe Incorporated | Multiple ring assembly for providing specimen to reaction receptacles within an automated analyzer |
US8337753B2 (en) | 1998-05-01 | 2012-12-25 | Gen-Probe Incorporated | Temperature-controlled incubator having a receptacle mixing mechanism |
AU2003271382B2 (en) * | 1998-05-01 | 2006-07-20 | Gen-Probe Incorporated | Automated Diagnostic Analyzer and Method |
ATE423622T1 (en) | 1998-05-01 | 2009-03-15 | Gen Probe Inc | AUTOMATIC ISOLATION AND AMPLIFICATION METHOD FOR A TARGET NUCLEIC ACID SEQUENCE |
DE19854003A1 (en) * | 1998-11-18 | 2000-05-25 | Jenoptik Jena Gmbh | Simultaneous magnetic particle handling in a two-dimensional arrangement |
WO2001002554A2 (en) * | 1999-07-05 | 2001-01-11 | MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. | Method for high-throughput selection of interacting molecules |
DE19954840A1 (en) * | 1999-11-09 | 2001-05-17 | Biopsytec Gmbh | Device for the preparation of biological samples for DNA analysis |
JP2002022752A (en) * | 2000-07-13 | 2002-01-23 | Suzuki Motor Corp | Specimen testing device |
DE10065148B4 (en) * | 2000-12-22 | 2004-01-22 | Institut für Physikalische Hochtechnologie e.V. | Magnetic gripping-holding arrangement |
CA2871777C (en) | 2005-03-10 | 2015-07-28 | Matthew J. Hayes | System and methods for detecting multiple optical signals |
CN103725591A (en) | 2010-07-23 | 2014-04-16 | 贝克曼考尔特公司 | Cartridge loading unit |
US9046507B2 (en) | 2010-07-29 | 2015-06-02 | Gen-Probe Incorporated | Method, system and apparatus for incorporating capacitive proximity sensing in an automated fluid transfer procedure |
WO2012116308A1 (en) | 2011-02-24 | 2012-08-30 | Gen-Probe Incorporated | Systems and methods for distinguishing optical signals of different modulation frequencies in an optical signal detector |
US9482684B2 (en) | 2011-11-07 | 2016-11-01 | Beckman Coulter, Inc. | Centrifuge system and workflow |
JP2014532881A (en) | 2011-11-07 | 2014-12-08 | ベックマン コールター, インコーポレイテッド | Magnetic braking for specimen transport systems |
BR112014011048A2 (en) | 2011-11-07 | 2017-05-02 | Beckman Coulter Inc | robotic arm |
BR112014011043A2 (en) | 2011-11-07 | 2017-06-13 | Beckman Coulter Inc | specimen container detection |
US9910054B2 (en) | 2011-11-07 | 2018-03-06 | Beckman Coulter, Inc. | System and method for processing samples |
JP6190380B2 (en) | 2011-11-07 | 2017-08-30 | ベックマン コールター, インコーポレイテッド | Equalizer system and workflow |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1986005815A1 (en) * | 1985-03-25 | 1986-10-09 | Genetics International Inc. | Nucleic acid sequences attached to materials sensitive to magnetic fields, and methods of assay and apparatus using such attached sequences. |
WO1990006045A2 (en) * | 1988-11-21 | 1990-06-14 | Dynal As | Nucleic acid probes |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU596987B2 (en) * | 1985-08-30 | 1990-05-24 | Tosoh Corporation | Automated immunoassay analyser |
FR2633310A1 (en) * | 1988-06-24 | 1989-12-29 | Pasteur Institut | REPEATED AUTOMATIC EXECUTION APPARATUS FOR A THERMAL CYCLE IN SEVERAL SUCCESSIVE STEPS, IN PARTICULAR FOR THE ENZYMATIC AMPLIFICATION OF NUCLEIC ACID SEQUENCES |
GB8816982D0 (en) * | 1988-07-16 | 1988-08-17 | Probus Biomedical Ltd | Bio-fluid assay apparatus |
CA2031912A1 (en) * | 1989-12-22 | 1991-06-23 | Robert Fred Pfost | Heated cover device |
DE69126690T2 (en) * | 1990-04-06 | 1998-01-02 | Perkin Elmer Corp | AUTOMATED LABORATORY FOR MOLECULAR BIOLOGY |
WO1992005443A1 (en) * | 1990-09-15 | 1992-04-02 | Medical Research Council | Reagent separation |
EP0479448A3 (en) * | 1990-10-02 | 1992-12-23 | Beckman Instruments, Inc. | Magnetic separation device |
-
1992
- 1992-06-09 GB GB929212164A patent/GB9212164D0/en active Pending
-
1993
- 1993-06-09 AU AU43439/93A patent/AU4343993A/en not_active Abandoned
- 1993-06-09 WO PCT/GB1993/001223 patent/WO1993025709A1/en active Application Filing
- 1993-06-09 WO PCT/GB1993/001222 patent/WO1993025912A2/en active Application Filing
- 1993-06-09 AU AU43440/93A patent/AU4344093A/en not_active Abandoned
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1986005815A1 (en) * | 1985-03-25 | 1986-10-09 | Genetics International Inc. | Nucleic acid sequences attached to materials sensitive to magnetic fields, and methods of assay and apparatus using such attached sequences. |
WO1990006045A2 (en) * | 1988-11-21 | 1990-06-14 | Dynal As | Nucleic acid probes |
Non-Patent Citations (1)
Title |
---|
ANALYTICAL BIOCHEMISTRY vol. 201, February 1992, NEW YORK US pages 166 - 169 ALDERTON ET AL. 'Magnetic bead purification of M13 DNA sequencing templates' cited in the application * |
Cited By (63)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5705628A (en) * | 1994-09-20 | 1998-01-06 | Whitehead Institute For Biomedical Research | DNA purification and isolation using magnetic particles |
US5898071A (en) * | 1994-09-20 | 1999-04-27 | Whitehead Institute For Biomedical Research | DNA purification and isolation using magnetic particles |
WO1996009379A1 (en) * | 1994-09-20 | 1996-03-28 | Whitehead Institute For Biomedical Research | Dna purification and isolation using a solid phase |
US8691969B2 (en) | 1994-12-12 | 2014-04-08 | Life Technologies As | Isolation of nucleic acid |
US5683875A (en) * | 1995-05-04 | 1997-11-04 | Hewlett-Packard Company | Method for detecting a target nucleic acid analyte in a sample |
US6828432B2 (en) | 1996-07-29 | 2004-12-07 | Nanosphere, Inc. | Nanoparticles having oligonucleotides attached thereto and uses therefor |
US6903207B2 (en) | 1996-07-29 | 2005-06-07 | Nanosphere, Inc. | Nanoparticles having oligonucleotides attached thereto and uses therefor |
US7098320B1 (en) | 1996-07-29 | 2006-08-29 | Nanosphere, Inc. | Nanoparticles having oligonucleotides attached thereto and uses therefor |
US7169556B2 (en) | 1996-07-29 | 2007-01-30 | Nanosphere, Inc. | Nanoparticles having oligonucleotides attached thereto and uses therefor |
US7208587B2 (en) | 1996-07-29 | 2007-04-24 | Nanosphere, Inc. | Nanoparticles having oligonucleotides attached thereto and uses therefor |
US6986989B2 (en) | 1996-07-29 | 2006-01-17 | Nanosphere, Inc. | Nanoparticles having oligonucleotides attached thereto and uses therefor |
US6984491B2 (en) | 1996-07-29 | 2006-01-10 | Nanosphere, Inc. | Nanoparticles having oligonucleotides attached thereto and uses therefor |
US6582921B2 (en) | 1996-07-29 | 2003-06-24 | Nanosphere, Inc. | Nanoparticles having oligonucleotides attached thereto and uses thereof |
US7250499B2 (en) | 1996-07-29 | 2007-07-31 | Nanosphere Inc. | Nanoparticles having oligonucleotides attached thereto and uses therefor |
US6610491B2 (en) | 1996-07-29 | 2003-08-26 | Nanosphere, Inc. | Nanoparticles having oligonucleotides attached thereto and uses therefor |
US7259252B2 (en) | 1996-07-29 | 2007-08-21 | Nanosphere, Inc. | Nanoparticles having oligonucleotides attached thereto and uses therefor |
US6969761B2 (en) | 1996-07-29 | 2005-11-29 | Nanosphere, Inc. | Nanoparticles having oligonucleotides attached thereto and uses therefor |
US6645721B2 (en) | 1996-07-29 | 2003-11-11 | Nanosphere, Inc. | Nanoparticles having oligonucleotides attached thereto and uses therefor |
US6673548B2 (en) | 1996-07-29 | 2004-01-06 | Nanosphere, Inc. | Nanoparticles having oligonucleotides attached thereto and uses therefor |
US6677122B2 (en) | 1996-07-29 | 2004-01-13 | Nanosphere, Inc. | Nanoparticles having oligonucleotides attached thereto and uses therefor |
US6682895B2 (en) | 1996-07-29 | 2004-01-27 | Nanosphere, Inc. | Nanoparticles having oligonucleotides attached thereto and uses therefor |
US6709825B2 (en) | 1996-07-29 | 2004-03-23 | Nanosphere, Inc. | Nanoparticles having oligonucleotides attached thereto and uses therefor |
US6720411B2 (en) | 1996-07-29 | 2004-04-13 | Nanosphere, Inc. | Nanoparticles having oligonucleotides attached thereto and uses therefor |
US6720147B2 (en) | 1996-07-29 | 2004-04-13 | Nanosphere, Inc. | Nanoparticles having oligonucleotides attached thereto and uses therefor |
US6730269B2 (en) | 1996-07-29 | 2004-05-04 | Nanosphere, Inc. | Nanoparticles having oligonucleotides attached thereto and uses therefor |
US6740491B2 (en) | 1996-07-29 | 2004-05-25 | Nanosphere, Inc. | Nanoparticles having oligonucleotides attached thereto and uses therefor |
US6750016B2 (en) | 1996-07-29 | 2004-06-15 | Nanosphere, Inc. | Nanoparticles having oligonucleotides attached thereto and uses therefor |
US6759199B2 (en) | 1996-07-29 | 2004-07-06 | Nanosphere, Inc. | Nanoparticles having oligonucleotides attached thereto and uses therefor |
US6767702B2 (en) | 1996-07-29 | 2004-07-27 | Nanosphere, Inc. | Nanoparticles having oligonucleotides attached thereto and uses therefor |
US6773884B2 (en) | 1996-07-29 | 2004-08-10 | Nanosphere, Inc. | Nanoparticles having oligonucleotides attached thereto and uses therefor |
US6777186B2 (en) | 1996-07-29 | 2004-08-17 | Nanosphere, Inc. | Nanoparticles having oligonucleotides attached thereto and uses therefor |
US6812334B1 (en) | 1996-07-29 | 2004-11-02 | Nanosphere, Inc. | Nanoparticles having oligonucleotides attached thereto and uses therefor |
US6818753B2 (en) | 1996-07-29 | 2004-11-16 | Nanosphere, Inc. | Nanoparticles having oligonucleotides attached thereto and uses therefor |
US6962786B2 (en) | 1996-07-29 | 2005-11-08 | Nanosphere, Inc. | Nanoparticles having oligonucleotides attached thereto and uses therefor |
US6861221B2 (en) | 1996-07-29 | 2005-03-01 | Nanosphere, Inc. | Nanoparticles having oligonucleotides attached thereto and uses therefor |
US6878814B2 (en) | 1996-07-29 | 2005-04-12 | Nanosphere, Inc. | Nanoparticles having oligonucleotides attached thereto and uses therefor |
US6902895B2 (en) | 1996-07-29 | 2005-06-07 | Nanosphere, Inc. | Nanoparticles having oligonucleotides attached thereto and uses therefor |
DE19801730A1 (en) * | 1998-01-19 | 1999-07-22 | Fraunhofer Ges Forschung | Analyzing cell contents, especially nucleic acids, useful for medical diagnostics |
US7115688B1 (en) | 1998-11-30 | 2006-10-03 | Nanosphere, Inc. | Nanoparticles with polymer shells |
DE19943374A1 (en) * | 1999-09-10 | 2001-03-29 | Max Planck Gesellschaft | Method for binding nucleic acids to a solid phase |
WO2001051665A2 (en) * | 2000-01-13 | 2001-07-19 | Nanosphere Inc. | Nanoparticles having oligonucleotides attached thereto and uses therefor |
WO2001051665A3 (en) * | 2000-01-13 | 2003-01-30 | Nanosphere Inc | Nanoparticles having oligonucleotides attached thereto and uses therefor |
US6974669B2 (en) | 2000-03-28 | 2005-12-13 | Nanosphere, Inc. | Bio-barcodes based on oligonucleotide-modified nanoparticles |
WO2001073123A3 (en) * | 2000-03-28 | 2003-02-06 | Nanosphere Inc | Nanoparticles having oligonucleotides attached thereto and uses therefor |
US7323309B2 (en) | 2000-03-28 | 2008-01-29 | Northwestern University | Bio-barcodes based on oligonucleotide-modified particles |
WO2001073123A2 (en) * | 2000-03-28 | 2001-10-04 | Nanosphere Inc. | Nanoparticles having oligonucleotides attached thereto and uses therefor |
US6602669B2 (en) | 2000-07-11 | 2003-08-05 | Northwestern University | Method of detection by enhancement of silver staining |
WO2002018643A3 (en) * | 2000-08-11 | 2003-09-04 | Nanosphere Inc | Nanoparticles having oligonucleotides attached thereto and uses therefor |
WO2002018643A2 (en) * | 2000-08-11 | 2002-03-07 | Nanosphere Inc. | Nanoparticles having oligonucleotides attached thereto and uses therefor |
US7282361B2 (en) | 2000-09-06 | 2007-10-16 | Transnetyx, Inc. | Systems and methods for transgenic and targeted mutagenesis screening |
US7494817B2 (en) | 2000-09-06 | 2009-02-24 | Transnet Yx, Inc. | Methods for genotype screening using magnetic particles |
US7011943B2 (en) | 2000-09-06 | 2006-03-14 | Transnetyx, Inc. | Method for detecting a designated genetic sequence in murine genomic DNA |
US6977178B2 (en) | 2000-09-06 | 2005-12-20 | Transnetyx, Inc. | System and method for transgenic and targeted mutagenesis screening |
WO2002046472A3 (en) * | 2000-12-08 | 2003-09-04 | Nanosphere Inc | Nanoparticles having oligonucleotides attached thereto and uses therefor |
WO2002046472A2 (en) * | 2000-12-08 | 2002-06-13 | Nanosphere, Inc. | Nanoparticles having oligonucleotides attached thereto and uses therefor |
US7238472B2 (en) | 2001-05-25 | 2007-07-03 | Nanosphere, Inc. | Non-alloying core shell nanoparticles |
US7135055B2 (en) | 2001-05-25 | 2006-11-14 | Nanosphere, Inc. | Non-alloying core shell nanoparticles |
US7147687B2 (en) | 2001-05-25 | 2006-12-12 | Nanosphere, Inc. | Non-alloying core shell nanoparticles |
US7186814B2 (en) | 2001-11-09 | 2007-03-06 | Nanosphere, Inc. | Bioconjugate-nanoparticle probes |
US7253277B2 (en) | 2002-07-02 | 2007-08-07 | Nanosphere, Inc. | Nanoparticle polyanion conjugates and methods of use thereof in detecting analytes |
US7527929B2 (en) | 2004-07-30 | 2009-05-05 | Agencourt Bioscience Corporation | Methods of isolating nucleic acids using multifunctional group-coated solid phase carriers |
WO2006059386A1 (en) * | 2004-12-02 | 2006-06-08 | National Institute Of Agrobiological Sciences | Method of isolating double-stranded dna containing simple sequence repeats |
JPWO2006059386A1 (en) * | 2004-12-02 | 2008-06-05 | 独立行政法人農業生物資源研究所 | Method for isolating double-stranded DNA containing simple repetitive sequence |
Also Published As
Publication number | Publication date |
---|---|
WO1993025912A2 (en) | 1993-12-23 |
WO1993025912A3 (en) | 1994-03-17 |
AU4344093A (en) | 1994-01-04 |
GB9212164D0 (en) | 1992-07-22 |
AU4343993A (en) | 1994-01-04 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO1993025709A1 (en) | Preparation of nucleic acids | |
EP0901531B1 (en) | Process for direct sequencing during template amplification | |
JP2839608B2 (en) | Method for detecting nucleic acid sequence | |
EP0929693B1 (en) | Multiplex polynucleotide capture methods and compositions | |
EP0385410A2 (en) | Partially double-stranded oligonucleotide and method for forming oligonucleotide | |
EP0763135B1 (en) | Producing copies of nucleic acids | |
EP0705349B1 (en) | Parallel primer extension approach to nucleic acid sequence analysis | |
JP2701092B2 (en) | Probe methods and compositions for detecting different DNA sequences | |
US5476769A (en) | Method for assays of nucleic acid, a reagent combination and a kit therefor | |
AU708678B2 (en) | Sequencing of nucleic acids | |
WO1991011533A1 (en) | Method for isolating primer extension products from template-directed dna polymerase reactions | |
JP2002512688A (en) | Nucleic acid archiving | |
WO1993006243A1 (en) | Dna cycle sequencing | |
US5601976A (en) | Method for detecting target nucleic acid in specimen | |
US5554503A (en) | Sample processing method for Mycobacterium tuberculosis | |
WO1993002212A1 (en) | Single step amplification and sequencing of nucleic acids | |
US5401632A (en) | Triple helix purification and sequencing | |
WO1998008981A1 (en) | METHODS FOR IDENTIFICATION AND ISOLATION OF SPECIFIC NUCLEOTIDE SEQUENCES IN cDNA AND GENOMIC DNA | |
US5770408A (en) | Method for the amplification of a base sequence | |
US5972611A (en) | Hybridization carrier and a process for preparing the same | |
EP0421469B1 (en) | Method for separating a target oligonucleotide | |
EP1114185B1 (en) | Method of isolating primer extension products with modular oligonucleotides | |
JP5128031B2 (en) | Method for producing nucleic acid introduced with label using RecA protein | |
AU660484B2 (en) | Single step amplification and sequencing of nucleic acids | |
WO2022008649A1 (en) | Spatial analysis of multiple targets in tissue samples |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AU JP US |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE |
|
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
122 | Ep: pct application non-entry in european phase |